NovoCure Limited
NVCRHealthcareNASDAQMedical Devices · Last scanned Sep 8, 2026
Scan Results
Daily timeframeNovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the. The company carries a $1.96B market cap, placing it firmly in the small-cap category. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax.
Market Cap
$1.96B
Beta
1.01
P/E (TTM)
—
P/E (Fwd)
-20.64
EPS (TTM)
$-1.30
EPS (Fwd)
$-0.82
ROE
-43.2%
ROA
-9.3%
Cash
$440.6M
Total Debt
$233.4M
Free CF
$22.8M
52W Change
46.9%
Annual Financials
Cash vs Debt
Where NVCR stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, NVCR finished 20.96% above its 150-day moving average ($14.74) and 24.77% above its 200-day moving average ($14.29). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NVCR overbought or oversold?
At the September 3, 2026 close, NVCR's RSI(14) was 53.8, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $440.6M in cash comfortably exceeding the $233.4M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $22.8M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -43.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $535.0M (2021) to $655.4M (2025), reflecting a 22% increase over the period.
Investors considering NovoCure Limited should weigh the typical risks associated with NVCR's sector, size, and financial profile against their own risk tolerance and investment objectives. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing NVCR.